Investing

Payments to Acquire in Process Research and Development

Eli Lilly Payments to Acquire in Process Research and Development decreased by 51.9% to $204.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 88.4%, from $1.76B to $204.00M. Over 3 years (FY 2021 to FY 2025), Payments to Acquire in Process Research and Development shows an upward trend with a 65.1% CAGR.

Analysis

StatementCash Flow Statement
SectionInvesting
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
Metric ID: investing_payments_to_acquire_in_process_research_and_de_b0355b

Historical Data

17 periods
 Q2 '21Q3 '21Q4 '21Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$167.15M$167.15M$167.15M$137.90M$235.00M$98.10M$3.03B$580.00M$96.50M$178.00M$2.82B$251.40M$1.76B$106.80M$720.50M$423.70M$204.00M
QoQ Change—+0.0%+0.0%-17.5%+70.4%-58.3%>999%-80.9%-83.4%+84.5%>999%-91.1%+598.9%-93.9%+574.6%-41.2%-51.9%
YoY Change———-17.5%———+320.6%-58.9%+81.4%-7.0%-56.7%>999%-40.0%-74.5%+68.5%-88.4%
Range$96.50M – $3.03B
CAGR+5.1%
Avg YoY Growth+168.0%
Median YoY Growth-17.5%
Current Streak2 quarters decline

Frequently Asked Questions

What is Eli Lilly's payments to acquire in process research and development?
Eli Lilly (LLY) reported payments to acquire in process research and development of $204.00M in Q1 2026.
How has Eli Lilly's payments to acquire in process research and development changed year-over-year?
Eli Lilly's payments to acquire in process research and development decreased by 88.4% year-over-year, from $1.76B to $204.00M.
What is the long-term trend for Eli Lilly's payments to acquire in process research and development?
Over 3 years (2021 to 2025), Eli Lilly's payments to acquire in process research and development has grown at a 65.1% compound annual growth rate (CAGR), from $668.60M to $3.01B.